Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MALIN L HULTCRANTZ

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1578921664
CMS profile
5405832
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,579.51

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,422.50 2
Food and Beverage $157.01 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $2,182.83 2
Janssen Scientific Affairs, LLC $1,396.68 2

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MALIN L HULTCRANTZ

NPI 1578921664 · CMS profile ID 5405832

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578921664?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MALIN L HULTCRANTZ, NPI 1578921664, CMS profile ID 5405832. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578921664?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MALIN L HULTCRANTZ, NPI 1578921664, CMS profile ID 5405832. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578921664?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MALIN L HULTCRANTZ, NPI 1578921664, CMS profile ID 5405832, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1578921664?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $3,579.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $135.3312/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988460553 CMS
Janssen Scientific Affairs, LLC $21.6809/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988572667 CMS
Janssen Biotech, Inc. $2,047.5007/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988460543 CMS
Janssen Scientific Affairs, LLC $1,375.0007/12/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988572663 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $451.18 7
PY2021 $1,830.00 2
PY2022 $4,540.45 3
PY2023 $3,579.51 4
PY2024 $9,375.22 7
PY2025 $8,299.71 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,507,253.15 50
PY2024 Principal investigator $621,082.28 99
PY2023 Recipient $50.00 1
PY2023 Principal investigator $320,573.02 53
PY2022 Principal investigator $98,174.79 7
PY2021 Principal investigator $56,106.62 10
PY2020 Principal investigator $64,226.75 8
PY2019 Recipient $840.72 11
PY2019 Principal investigator $100,589.30 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeiGene, Ltd. $1,254.00 12/13/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043037777
Principal investigator 1 BeiGene, Ltd. $3,829.00 12/13/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043042002
Principal investigator 1 BeiGene, Ltd. $1,254.00 12/13/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043066047
Principal investigator 1 BeiGene, Ltd. $1,254.00 12/13/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043071765
Principal investigator 1 BeiGene, Ltd. $2,007.00 12/13/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043072507
Principal investigator 1 BeiGene, Ltd. $3,829.00 12/13/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043073217
Principal investigator 1 BeiGene, Ltd. $2,007.00 12/13/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043074559
Principal investigator 1 BeiGene, Ltd. $3,829.00 12/13/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043095565
Principal investigator 1 BeiGene, Ltd. $2,007.00 12/13/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043114273
Principal investigator 1 BeiGene, Ltd. $1,254.00 12/13/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043114669
Recipient AbbVie Inc. $50.00 12/08/2023 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 998353623
Principal investigator 1 GlaxoSmithKline, LLC. $3,442.80 11/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CENTER-NEW
214643 No dispute reported 06/30/2026 1006133981
Principal investigator 1 BeiGene, Ltd. $5,733.00 11/15/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043066017
Principal investigator 1 BeiGene, Ltd. $1,254.00 11/15/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043068155
Principal investigator 1 BeiGene, Ltd. $5,784.00 11/15/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043069057
Principal investigator 1 BeiGene, Ltd. $3,829.00 11/15/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043069525
Principal investigator 1 BeiGene, Ltd. $5,784.00 11/15/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043094973
Principal investigator 1 BeiGene, Ltd. $1,254.00 11/15/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043096715
Principal investigator 1 BeiGene, Ltd. $2,007.00 11/15/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043114385
Principal investigator 1 BeiGene, Ltd. $5,733.00 11/15/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043115583
Principal investigator 1 BeiGene, Ltd. $2,926.00 10/27/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043040173
Principal investigator 1 BeiGene, Ltd. $2,600.00 10/27/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043040389
Principal investigator 1 BeiGene, Ltd. $2,341.00 10/27/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043041789
Principal investigator 1 BeiGene, Ltd. $1,756.00 10/27/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043065283
Principal investigator 1 BeiGene, Ltd. $2,341.00 10/27/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043066095
Principal investigator 1 BeiGene, Ltd. $5,974.00 10/27/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043073789
Principal investigator 1 BeiGene, Ltd. $3,250.00 10/27/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043096797
Principal investigator 1 BeiGene, Ltd. $2,458.00 10/27/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043111065
Principal investigator 1 BeiGene, Ltd. $1,216.00 10/27/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043112497
Principal investigator 1 BeiGene, Ltd. $2,007.00 10/18/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043040405
Principal investigator 1 BeiGene, Ltd. $3,829.00 10/18/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043072557
Principal investigator 1 BeiGene, Ltd. $2,007.00 10/18/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043073051
Principal investigator 1 BeiGene, Ltd. $5,784.00 10/18/2023 Non-covered Recipient Entity
Memorial SloanKettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043073117
Principal investigator 1 BeiGene, Ltd. $1,254.00 10/18/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043094359
Principal investigator 1 BeiGene, Ltd. $5,733.00 10/18/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043110873
Principal investigator 1 ABBVIE INC. $6,982.62 10/04/2023 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed; Refractory Multiple Myeloma No dispute reported 06/30/2026 998402393
Principal investigator 1 GlaxoSmithKline, LLC. $4,131.36 09/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CENTER-NEW
214643 No dispute reported 06/30/2026 1006133991
Principal investigator 1 BeiGene, Ltd. $60,318.00 08/28/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1043099922
Principal investigator 1 GlaxoSmithKline, LLC. $21,973.84 07/06/2023 Non-covered Recipient Entity
SLOAN KETTERING INS FOR CANCER RES
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1006133969
Principal investigator 1 GlaxoSmithKline, LLC. $1,688.26 05/17/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1006132525
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 05/17/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1006132533
Principal investigator 1 GlaxoSmithKline, LLC. $2,273.00 05/17/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1006132543
Principal investigator 1 GlaxoSmithKline, LLC. $2,813.77 05/17/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1006132553
Principal investigator 1 GlaxoSmithKline, LLC. $2,273.00 05/17/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1006133885
Principal investigator 1 GlaxoSmithKline, LLC. $6,820.57 05/17/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1006133893
Principal investigator 1 GlaxoSmithKline, LLC. $1,136.00 05/17/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1006133927
Principal investigator 1 GlaxoSmithKline, LLC. $2,622.54 05/17/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1006133937
Principal investigator 1 GlaxoSmithKline, LLC. $2,341.00 05/17/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1006133947
Principal investigator 1 GlaxoSmithKline, LLC. $5,477.57 05/17/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1006133955
Principal investigator 1 GlaxoSmithKline, LLC. $4,182.56 05/15/2023 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
CHARACTERIZATION OF CORNEAL EPITHELIAL CHANGES IN PARTICIPANTS TREATED No dispute reported 06/30/2026 1006133917
Principal investigator 1 GlaxoSmithKline, LLC. $3,599.44 04/10/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE II, OPEN LABEL, RANDOMIZED, TWO-ARM STUDY TO INVESTIGATE THE E No dispute reported 06/30/2026 1006133875
Principal investigator 1 GlaxoSmithKline, LLC. $7,540.69 03/06/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CEN
Not supplied No dispute reported 06/30/2026 1006132515
Principal investigator 1 GlaxoSmithKline, LLC. $78,548.00 03/06/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CEN
Not supplied No dispute reported 06/30/2026 1006134001
Principal investigator 1 GlaxoSmithKline, LLC. $1,030.00 01/03/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH-RETAIL
A PHASE II, OPEN LABEL, RANDOMIZED, TWO-ARM STUDY TO INVESTIGATE THE E No dispute reported 06/30/2026 1006133907